肽受体放射性核素治疗影像学缓解对转移性中肠神经内分泌肿瘤患者总生存的影响
该研究纳入133例连续接受PRRT的进展期转移性中肠NET患者,按PRRT后1年缓解情况(部分缓解、疾病稳定、疾病进展或死亡)分组评估生存。PRRT后1年达疾病稳定者与部分缓解者总生存相似,肝肿瘤负荷大于50%是PRRT缓解、PFS和OS的强预测因素。
要点
- PRRT后1年9%部分缓解、50.4%疾病稳定、10.5%疾病进展、30.1%死亡,OS为33.5个月、PFS为28.5个月。
- 部分缓解与疾病稳定患者PRRT后总生存无差异。
- 肝肿瘤负荷大于50%是PRRT缓解、PFS和OS的强预测因素。
核心结论
- 进展期转移性中肠NET患者PRRT后1年达疾病稳定者与部分缓解者总生存相似。
- 肝肿瘤负荷是PRRT缓解、PFS和OS的强预测因素。
研究设计与样本
- 研究纳入133例连续接受PRRT的进展期转移性中肠NET患者,按PRRT后1年缓解情况(部分缓解、疾病稳定、疾病进展或死亡)分组评估生存,并分析OS和PFS的预测因素。
主要发现
- PRRT后1年9%部分缓解、50.4%疾病稳定、10.5%疾病进展、30.1%死亡,OS为33.5个月、PFS为28.5个月。
- 疾病进展或死亡的预测因素为嗜铬粒蛋白A大于10倍正常值上限(OR 4.6,P=0.007)和肝肿瘤负荷大于50%(OR 5,P=0.004)。
- 部分缓解与疾病稳定患者PRRT后总生存无差异。
- 多因素Cox回归中OS预测因素为PRRT周期数(HR 0.33,P<0.0005)、肝肿瘤负荷大于50%(HR 3.46,P=0.01)和PRRT后1年结局(HR 21.37,P<0.0005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE OF THE REPORT: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced neuroendocrine tumors (NET); however, long-term survival data are scarce. The aim of this study is to determine long-term survival in patients with metastatic midgut NET, according to response to PRRT. PATIENTS AND METHODS: One hundred thirty-three consecutive patients with progressive metastatic midgut NET underwent PRRT. Response at 1 year post PRRT was classified as partial response, stable disease, disease progression, or death. Survival was assessed according to response to PRRT, and predictors of overall survival (OS) and progression-free survival (PFS) were identified. RESULTS: At 1 year post PRRT, 9% had partial response, 50.4% stable disease, 10.5% disease progression, and 30.1% were dead. The OS was 33.5, and PFS was 28.5 months. Predictors of disease progression/death were chromogranin A greater than 10 ULN (OR, 4.6; P = 0.007) and hepatic tumor load greater than 50% (OR, 5; P = 0.004). There was no difference in OS between patients with partial response and those with stable disease post PRRT. In multivariate Cox regression, predictors of OS were number of PRRT cycles (HR, 0.33; P < 0.0005), hepatic tumor load greater than 50% (HR, 3.46; P = 0.01), and outcome at 1 year post PRRT (HR, 21.37; P < 0.0005). Predictors of PFS were number of PRRT cycles (HR, 0.39; P < 0.0005), previous resection of liver metastases (HR, 3.56; P = 0,023), and hepatic tumor load greater than 50% (HR, 3.06; P < 0.0005). CONCLUSIONS: Patients with progressive metastatic midgut NET who achieved stable disease at 1 year post PRRT had similar OS with those with partial response. Hepatic tumor burden was a strong predictor of response to PRRT, PFS, and OS.
引用
- Yalchin M, Oliveira A, Theocharidou E, et al. The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors. Clin Nucl Med. 2017. PMID: 27922860. doi:10.1097/RLU.0000000000001457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。